| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
This trial is included in the following systematic reviews and meta-analyses:
Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
Fiessinger study, 2005 |
|
Treatments
| Studied treatment |
ximelagatran 36 mg twice daily
|
| Control treatment |
subcutaneous enoxaparin, 1 mg/kg twice daily, for 5 to 20 days followed by warfarin adjusted to maintain an international normalized ratio of 2.0 to 3.0.
|
Patients
| Patients | patients with acute deep vein thrombosis |
Method and design
| Randomized effectives | NA / NA (studied vs. control) |
| Blinding | double blind |
| Number of centre | 279 |
| Primary endpoint | 28 countries |
Results
No results available for this trial - no clinical endpoint reported
Reference(s)
| Trials register # | NA |
-
Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstr�m T, Berkowitz SD, Nystr�m P, Thors�n M, Ginsberg JS.
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial..
JAMA 2005 Feb 9;293:681-9
Pubmed
|
Hubmed
| Fulltext
(c) 2004-2010 TrialResults-center - All Rights Reserved
Tweet this
notify a friend